Theranexus
Clinical-stage biopharmaceutical company developing treatments for rare neurological disorders.
ALTHX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013286259
- LEI:
- 969500BFCV6IC7MFQP20
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://www.theranexus.com/en/
- Sector:
- Manufacturing
Description
THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-10-17 18:00 |
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2023
|
English | 253.1 KB | ||
| 2023-10-17 18:00 |
THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 30 SEPTEMBRE 2023
|
French | 230.9 KB | ||
| 2023-09-29 07:30 |
Theranexus : Highly Promising 12-month results in the Phase I/II trial of Batte…
|
English | 459.5 KB | ||
| 2023-09-29 07:30 |
Theranexus : Résultats très prometteurs à 12 mois dans l'étude de phase 1/2 de …
|
French | 434.2 KB | ||
| 2023-09-28 18:00 |
THERANEXUS ANNOUNCES FIRST HALF 2023 FINANCIAL RESULTS
|
English | 324.9 KB | ||
| 2023-09-28 18:00 |
THERANEXUS ANNONCE SES RÉSULTATS FINANCIERS DU PREMIER SEMESTRE 2023
|
French | 322.2 KB | ||
| 2023-08-30 18:00 |
Information mensuelle relative au nombre total de droits de vote et d'actions c…
|
French | 240.4 KB | ||
| 2023-07-12 07:30 |
Theranexus raises around 3.1 million euros in fundraising
|
English | 299.7 KB | ||
| 2023-07-12 07:30 |
Theranexus réalise une levée de fonds d''un montant d''environ 3,1 millions d''…
|
French | 329.9 KB | ||
| 2023-07-11 17:40 |
Theranexus lance une levée de fonds d''un montant d''environ 4 millions d''euro…
|
French | 305.1 KB | ||
| 2023-07-06 18:00 |
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONFIÉ A PORTZAMPARC
|
French | 341.0 KB | ||
| 2023-06-14 07:30 |
Résultats préliminaires encourageants à 6 mois dans l'étude de phase 1/2 de Bat…
|
French | 445.6 KB | ||
| 2023-06-14 07:30 |
Encouraging preliminary 6-month results in the Phase I/II trial of Batten-1 in …
|
English | 465.1 KB | ||
| 2023-06-07 07:30 |
Theranexus et BBDF obtiennent l'avis positif de l'EMA sur le design de la phase…
|
French | 408.7 KB | ||
| 2023-05-24 18:00 |
MISE A DISPOSITION DES INFORMATIONS RELATIVES A L'ASSEMBLÉE GÉNÉRALE DES ACTION…
|
French | 206.1 KB |
Automate Your Workflow. Get a real-time feed of all Theranexus filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Theranexus
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Theranexus via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
